Fairvalue-Calculator Fairvalue-Calculator
EN DE

4basebio PLC (4BB) Fair Value & Analysis

Healthcare · GB · Market cap 81.3M GBX

Pricep5.25
Fair Valuep2.94
Upside-44.0%
Quality95/100
Evidence: Low Range p2.20 – p3.67

Fair value as of: Jun 24, 2026

Analysis

4basebio PLC (4BB) currently trades at p5.25, while our model-based Fair Value estimate is p2.94 — implying the stock looks roughly 44.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome editing; osDNA, a DNA product that incorporates nucleotide modifications within the DNA backbone; and Hermes, a nanoparticle platform. The company also provides custom pegRNA and sgRNA manufacturing; and nanoparticle formulation services. Its products are used in mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines, and non-viral delivery applications. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and i…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is 4basebio PLC (4BB) undervalued?
As of Jun 24, 2026, our model estimates a fair value of p2.94 versus a price of p5.25 — about −44% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4BB?
Our 21-model fair value for 4basebio PLC is p2.94 (as of Jun 24, 2026), built from audited fundamentals. The current price is p5.25.
What is the quality score of 4BB?
4basebio PLC has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.